Research ArticleHEALTH AND MEDICINE
Targeted delivery of antisense oligonucleotides to pancreatic β-cells
- C. Ämmälä1,*,
- W. J. Drury III1,
- L. Knerr1,
- I. Ahlstedt1,
- P. Stillemark-Billton1,
- C. Wennberg-Huldt1,
- E.-M. Andersson1,
- E. Valeur1,
- R. Jansson-Löfmark1,
- D. Janzén1,
- L. Sundström2,
- J. Meuller2,
- J. Claesson2,
- P. Andersson3,
- C. Johansson3,
- R. G. Lee4,
- T. P. Prakash4,
- P. P. Seth4,*,
- B. P. Monia4 and
- S. Andersson1
- 1Cardiovascular Renal and Metabolic Diseases, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
- 2Discovery Sciences, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
- 3Drug Safety and Metabolism, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
- 4Ionis Pharmaceuticals, 2855 Gazelle Court, Carlsbad, CA 92010, USA.
- ↵*Corresponding author. Email: carina.ammala{at}astrazeneca.com (C.Ä.); pseth{at}ionisph.com (P.P.S.)
See allHide authors and affiliations
Science Advances 17 Oct 2018:
Vol. 4, no. 10, eaat3386
DOI: 10.1126/sciadv.aat3386
Vol. 4, no. 10, eaat3386
DOI: 10.1126/sciadv.aat3386
C. Ämmälä
Cardiovascular Renal and Metabolic Diseases, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
W. J. Drury
Cardiovascular Renal and Metabolic Diseases, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
L. Knerr
Cardiovascular Renal and Metabolic Diseases, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
I. Ahlstedt
Cardiovascular Renal and Metabolic Diseases, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
P. Stillemark-Billton
Cardiovascular Renal and Metabolic Diseases, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
C. Wennberg-Huldt
Cardiovascular Renal and Metabolic Diseases, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
E.-M. Andersson
Cardiovascular Renal and Metabolic Diseases, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
E. Valeur
Cardiovascular Renal and Metabolic Diseases, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
R. Jansson-Löfmark
Cardiovascular Renal and Metabolic Diseases, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
D. Janzén
Cardiovascular Renal and Metabolic Diseases, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
L. Sundström
Discovery Sciences, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
J. Meuller
Discovery Sciences, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
J. Claesson
Discovery Sciences, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
P. Andersson
Drug Safety and Metabolism, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
C. Johansson
Drug Safety and Metabolism, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
R. G. Lee
Ionis Pharmaceuticals, 2855 Gazelle Court, Carlsbad, CA 92010, USA.
T. P. Prakash
Ionis Pharmaceuticals, 2855 Gazelle Court, Carlsbad, CA 92010, USA.
P. P. Seth
Ionis Pharmaceuticals, 2855 Gazelle Court, Carlsbad, CA 92010, USA.
B. P. Monia
Ionis Pharmaceuticals, 2855 Gazelle Court, Carlsbad, CA 92010, USA.
S. Andersson
Cardiovascular Renal and Metabolic Diseases, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
